Novartis capmatinib (INC280) received breakthrough designation by FDA

Updated: Apr 4, 2020

Novartis announced that capmatinib (INC280) received the breakthrough designation. The product is the first drug indicated for the first line and second-line treatment.

FDA gives breakthrough designation for the drugs which are indicated for serious or life-threatening disease. The therapies are expected to provide substantial benefit.

The drug received the breakthrough designation based on the GEOMETRY mono-1 study, which was presented in the American Society of Clinical Oncology (ASCO) 2019.

Capmatinib is a potent and selective MET inhibitor. MET mutation is identified in 3-4% of all the patients suffering from NSCLC.

The drug was originally developed by Incyte.

The drug is expected to release in Q4 of 2019.


Please donate to support iPharmaCenter. Click on donate button in header to support us. Thank you

©2020 by ipharmaservices